History
Pancreatic cancer is a general term for cancers that arise in the pancreas, but pancreatic ductal adenocarcinoma, which begins in the pancreatic ducts, is generally the most common, so “pancreatic cancer” often refers to this disease. The pancreas is located deep behind the stomach, and even when early lesions develop, outwardly noticeable symptoms appear late. For this reason, pancreatic cancer has historically been regarded as a cancer that is diagnosed late and has a very poor prognosis.
Medically, the diagnosis of pancreatic cancer began in earnest with advances in imaging and endoscopic technology. In the past, it was often confirmed through surgery or autopsy, but as computed tomography and magnetic resonance imaging became widespread, pancreatic masses could be seen relatively accurately. Later, with the introduction of endoscopic ultrasound, small lesions could be found more easily, and the process of obtaining tissue with a needle to confirm the diagnosis became more refined.
Recent research shows that the strategy of combining preoperative chemotherapy (neoadjuvant therapy) and postoperative chemotherapy (adjuvant therapy) to reduce recurrence has become standard, and with the introduction of multidrug chemotherapy, there has been a trend of gradually improving survival. In addition, as the concept has spread that targeted therapy can help when a genetic abnormality (e.g., a BRCA gene mutation) is identified in some patients, pancreatic cancer is also gradually entering the realm of “precision treatment.”
Causes
It is difficult to pin down the cause of pancreatic cancer to one thing. It is generally understood as a process in which pancreatic cells accumulate genetic damage and begin uncontrolled proliferation. The most certain lifestyle risk factor is smoking. Smoking raises the risk of pancreatic cancer, and some of all patients are estimated to have cancer associated with smoking.
Obesity and diabetes are also associated with risk. In particular, there is discussion that newly developed diabetes may be both a risk factor for pancreatic cancer and an early signal of it. Heavy drinking can raise the risk indirectly through chronic pancreatitis, and chronic pancreatitis itself is known to be an important risk factor. Regarding diet, there are reports that consumption of processed meat and red meat is associated with risk, but an individual's actual risk is determined by several factors together.
Ultimately, it is more accurate to understand the causes of pancreatic cancer as a combination, over a long period, of genetic predisposition, lifestyle factors such as smoking and obesity, chronic inflammation such as pancreatitis, and metabolic diseases. The key point is that the complex interaction of several risk factors, rather than a single cause, produces pancreatic cancer.
Genetic Epidemiology
An important point in the genetic epidemiology of pancreatic cancer is that genetic susceptibility is clearly involved in some patients. About 5–10% of all pancreatic cancers are known to be possibly related to inherited gene mutations and familial clustering. When there are several pancreatic cancer patients in the family, or when it is diagnosed at a relatively young age, a genetic cause is considered more actively.
Representative genes associated with genetic predisposition include BRCA1 and BRCA2, Lynch syndrome-related genes, the ATM gene, and the PALB2 gene. These genetic variants can not only raise the risk of pancreatic cancer but, in some cases, also affect the choice of treatment.
Recent research shows a strengthening trend of performing genetic testing on patients at the time of pancreatic cancer diagnosis to find treatable targets, and of connecting family members to genetic counseling and high-risk surveillance. However, even without a gene mutation, the risk can increase if there is a family history, and even with a gene mutation, individual risk can vary depending on factors such as age, smoking, and a history of pancreatitis.
General Epidemiology
Pancreatic cancer is known as a cancer whose incidence is lower than that of other common cancers but whose mortality is very high. The reason is that it has often already progressed at diagnosis and is often highly resistant to treatment. Many countries have reported increasing trends in the incidence and mortality of pancreatic cancer, and in some regions, it has been projected to rise to the top of the causes of cancer death in the future.
Pancreatic cancer generally increases after age 40 and is more common in older adults. It occurs in both men and women, but a tendency to be somewhat more common in men has been noted. At the time of diagnosis, only a minority (roughly 10–15%) are at a localized stage that can be resected, and a considerable number are diagnosed at a locally advanced or metastatic stage.
Recent research emphasizes “identifying high-risk groups more accurately to increase early detection” as the key to reducing the epidemiological burden of pancreatic cancer. Changes in smoking rates, increases in obesity and diabetes, and population aging are cited as factors increasing the burden of pancreatic cancer, and managing risk factors is central to both prevention and early detection.
Pathogenesis
The pathogenesis of pancreatic ductal adenocarcinoma is explained as a process in which precancerous lesions progress to invasive cancer through multiple stages of genetic change. Cells lining the pancreatic ducts change abnormally to produce precancerous changes, which develop into invasive cancer over time. In this process, KRAS gene mutations typically appear commonly at a very early stage, followed by the accumulation of abnormalities in several genes involved in cell cycle regulation and tumor suppression, which is understood to increase the aggressiveness of the cancer.
In pancreatic cancer, not only the cancer cells themselves but also the surrounding environment is very important. Pancreatic cancer forms a thick fibrous stroma (like a “hard wall”), creating an environment in which drugs have difficulty reaching the cancer cells and immune cells have difficulty penetrating. For this reason, immunotherapy, which works well in other cancers, is often of limited effect in pancreatic cancer.
Recent research shows advances in strategies to restore the immune response by modulating the tumor microenvironment, or to precisely identify small groups of patients with specific molecular abnormalities and apply targeted therapy. Ultimately, the pathogenesis of pancreatic cancer can be understood as “the accumulation of genetic changes” and “a tumor environment unfavorable to treatment” working together.
Symptoms
Pancreatic cancer often causes no symptoms in its early stages. Even when symptoms appear, they begin as nonspecific symptoms such as indigestion, upper abdominal discomfort, and fatigue, and are easily mistaken for other conditions. Commonly reported symptoms are unexplained weight loss, loss of appetite, and abdominal pain or back pain. The pain is sometimes described as worsening after meals or when lying down and easing when bending the body forward.
If a tumor develops in the head of the pancreas and blocks the bile duct, jaundice can occur. The skin and eyes may turn yellow, the urine may become darker, the stool may become paler, and itching may accompany it. Also, if the pancreas cannot produce enough digestive enzymes, digestive symptoms such as fatty stools (steatorrhea), diarrhea, and abdominal bloating can appear.
As it progresses, nausea, vomiting, ascites, thrombosis, and general weakness can appear, and metastasis can cause symptoms such as liver enlargement and bone pain. Because these symptoms can also appear in other conditions, it is important for people with risk factors to be evaluated when they notice new symptoms.
Signs
On physical examination, there are almost no distinct signs of pancreatic cancer in its early stages. In advanced cases, jaundice, scratch marks from itchy skin, weight loss, abdominal distension, ascites, and liver enlargement may be observed. When the bile duct is blocked, blood tests show elevated bilirubin and hepatobiliary enzymes.
Among tumor markers, carbohydrate antigen 19-9 (CA 19-9) is used to track treatment response or recurrence, but it has limitations as a screening tool for early diagnosis. CA 19-9 can also rise in other biliary diseases or inflammation, and some people may be unable to produce it at all for genetic reasons.
Imaging tests provide the key signs. The presence of a pancreatic mass, dilation of the bile duct and pancreatic duct, invasion of surrounding blood vessels, lymph node metastasis, and liver metastasis is evaluated on computed tomography and magnetic resonance imaging. Endoscopic ultrasound plays an important role in finding small lesions and obtaining tissue.
Screening
Because pancreatic cancer has a low incidence and screening tests carry considerable harms and costs, screening of the general population is known not to be effective. Screening therefore focuses on high-risk groups. High-risk groups can include certain hereditary syndromes, a strong family history (several first-degree relatives with pancreatic cancer), hereditary pancreatitis, and others.
In screening high-risk groups, a strategy combining magnetic resonance imaging and endoscopic ultrasound is often discussed. Endoscopic ultrasound has high sensitivity for finding small tumors and can lead directly to a biopsy if necessary. Magnetic resonance imaging involves no radiation exposure and helps evaluate lesions such as pancreatic cysts.
Recent research proposes setting the starting age and testing interval for high-risk screening differently according to the type of gene and family history. However, even high-risk screening is not yet standardized in all countries, and further accumulation of evidence on how much it actually improves survival is still needed.
Diagnosis
Diagnosis of pancreatic cancer usually proceeds in the sequence “confirming a mass on imaging → staging → confirming by biopsy.” The most fundamental imaging is pancreas-protocol computed tomography. Through it, the location and size of the tumor and its relationship to major blood vessels are evaluated to determine surgical resectability (resectable, borderline resectable, locally advanced).
If the bile duct is blocked and jaundice is severe, a stent is sometimes placed in the bile duct endoscopically to help drainage. Biopsy is often performed by endoscopic ultrasound-guided fine-needle aspiration. Evaluating metastasis requires whole-body imaging including the liver and peritoneum, and in some cases positron emission tomography may be used as an adjunct.
Recent research is investigating technologies such as liquid biopsy (a method of finding tumor-derived DNA and the like in the blood), but imaging and biopsy remain at the center of standard diagnosis today. Accurate staging is the most important first step in establishing the optimal treatment plan.
Treatment
Treatment of pancreatic cancer differs greatly depending on the stage and the patient's general condition. Cure can be hoped for when the tumor can be completely removed by surgery. Representative operations include pancreaticoduodenectomy (the Whipple procedure) and distal pancreatectomy, and because these operations are technically demanding, managing complications is important. Even when surgery is possible, the risk of recurrence is high, so postoperative chemotherapy is given as standard.
Recent research has presented evidence that multidrug chemotherapy can improve survival, leading to a trend toward more intensive postoperative treatment. In addition, for borderline resectable or locally advanced disease, a strategy of attempting surgery after first shrinking the tumor or suppressing micrometastases with preoperative chemotherapy is widely used. In metastatic pancreatic cancer, chemotherapy is central, and palliative care such as pain control, drainage for jaundice, and nutritional management is very important.
When specific molecular abnormalities such as a BRCA gene mutation are identified in some patients, targeted therapy can help, and in rare cases with specific immune abnormalities, immunotherapy may be considered. Recent research has shown meaningful responses to immunotherapy in certain small patient groups, and research to find out “who benefits” is ongoing.
Prognosis
Pancreatic cancer is known as a cancer with a poor prognosis. The key reasons are that early diagnosis is difficult and that it is often already advanced or metastatic and unresectable at diagnosis. Unlike cancers such as prostate or breast cancer, in which early lesions are frequently found by screening, pancreatic cancer is commonly asymptomatic early on, so it tends to be discovered late.
Prognosis depends greatly on the stage and whether surgery is possible. If complete surgical resection is possible and adjuvant chemotherapy can also be received, the likelihood of long-term survival rises, but the risk of recurrence is still high. Recent research shows that survival is gradually improving with multidrug chemotherapy and perioperative treatment strategies, but there is also the assessment that the extent of improvement is limited.
When discussing prognosis, quality of life is very important. Pain, digestive problems, weight loss, depression and anxiety, and treatment side effects can accompany the disease, so palliative care and nutrition and pain management need to be provided alongside treatment from an early stage.
Prevention
Reliable primary prevention of pancreatic cancer is limited, but lifestyle habits that lower the risk are relatively clear. Quitting smoking is the most important preventive strategy. Keeping body weight in a healthy range, exercising regularly, and managing diabetes well are also helpful. Because heavy drinking can be linked to chronic pancreatitis, moderating alcohol intake is important.
In high-risk groups, lifestyle alone may not be enough, so surveillance tailored to the level of risk becomes key. When there is a strong family history or a specific genetic variant has been identified, the timing and method of testing (magnetic resonance imaging, endoscopic ultrasound, etc.) are planned through genetic counseling.
For the general public, the most realistic prevention is “avoiding smoking, managing metabolic health, and not ignoring new symptoms.” In particular, if there are symptoms such as unexplained weight loss, newly developed diabetes, persistent upper abdominal or back pain, or jaundice, it is important to be evaluated without delay.